Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Serco revenues dip in line with guidance, underlying operating profit up 10%

(Sharecast News) - Outsourcer Serco posted a dip in full-year revenue on Thursday, in line with its guidance, and a 10% jump in underlying operating profit. In the year to the end of December 2024, reported revenue nudged down 2% to £4.8bn, while underlying operating profit rose to £274m from £249m.

Reported operating profit was 52% lower at £130m due to an exceptional £115m non-cash goodwill impairment charge in Asia Pacific.

The underlying operating margin improved 60 basis points to 5.7% with progress in all regions, Serco said, "reflecting ongoing focus on efficiency and productivity".

The order intake rose 7% to £4.9bn and Serco hailed "very strong" free cash flow of £228m, ahead of guidance of about £170m.

As far as the outlook for 2025 is concerned, Serco said it expects revenue to be similar to 2024, with underlying organic growth of 7% offsetting reductions in the UK and Australian immigration contracts.

Chief executive Mark Irwin said: "Our 2024 results reflect another year of strong operational and financial delivery across the group.

"We accelerated trading momentum through the second half of the year, which allowed us to achieve full year revenue in line with guidance, underlying operating profit up 10%, a 60 basis point increase in margins and deliver significantly more free cash flow than initially expected. We had excellent order intake of £4.9bn resulting in a robust £13bn order book, and we ended the year with a strong pipeline of qualified new business opportunities exceeding £11bn to underpin future growth."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.